Smaller samples, more data
Despite being broadly used for a variety of tasks in the clinic, proteomic analysis has limitations that impede its routine use in the analysis of clinical cancer specimens because techniques such as flow cytometry and western blot analysis require laborious preparation steps and large volumes of clinical samples. Researchers at Stanford Universityand Cell Biosciences Inc. are looking to change that with an automated protein analysis system, and they have developed the first clinically applicable assay for the technology.1
The assay, which can be analyzed using the biotech's newly launched CB1000 protein analysis system, showed that changes in mitogen-activated protein kinase 1 (MAPK1; ERK-2) phosphorylation could be associated with responsiveness to cancer therapy...